Press Releases

Category:

Year:

DocumentYearTerms

05/16/2018 - 7:30 am | Corporate

DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors

Download PDF (346 KB)

05/14/2018 - 6:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (256 KB)

05/14/2018 - 2:30 pm | Corporate

DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week

Download PDF (356 KB)

05/08/2018 - 7:30 am | Medical Congresses

DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting

Download PDF (460 KB)

05/01/2018 - 7:30 am | Corporate

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (306 KB)

04/27/2018 - 7:30 am | Finance

DBV Technologies Reports March 31, 2018 Cash Position

Download PDF (316 KB)

04/05/2018 - 6:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (156 KB)

04/03/2018 - 7:30 am | Conferences

DBV Technologies to Attend the 11th Kempen Life Sciences Conference

Download PDF (289 KB)

03/26/2018 - 10:00 pm | Finance

DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Shares in Global Offering

Download PDF (321 KB)

03/23/2018 - 9:00 pm | Finance

DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Download PDF (324 KB)

03/21/2018 - 8:14 am | Finance

DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

Download PDF (458 KB)

03/20/2018 - 9:01 pm | Finance

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares

Download PDF (479 KB)

03/16/2018 - 9:30 pm | Corporate | Finance

DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

Download PDF (319 KB)

03/14/2018 - 2:30 am | Finance

DBV Technologies Reports Full Year 2017 Financial Results

Download PDF (398 KB)

03/07/2018 - 1:30 am | Conferences

DBV Technologies to Present at the Barclays Global Healthcare Conference

Download PDF (314 KB)

02/28/2018 - 9:07 pm | Corporate

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (156 KB)

02/26/2018 - 10:45 pm | Clinical

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

Download PDF (1 MB)

02/20/2018 - 7:30 am | Finance

DBV Technologies Reports December 31, 2017 Cash Position

Download PDF (924 KB)

02/14/2018 - 7:30 am | Clinical

DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut

Download PDF (1,017 KB)

02/13/2018 - 2:16 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (158 KB)

02/12/2018 - 3:00 pm | Science

DBV Technologies to Highlight Viaskin Technology Platform at the 2018 AAAAI/WAO Joint Congress

Download PDF (1 MB)

02/01/2018 - 7:30 am | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (643 KB)

01/16/2018 - 7:30 am | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with Natixis

Download PDF (643 KB)

01/12/2018 - 4:08 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (159 KB)

01/03/2018 - 7:30 am | Conferences

DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference

Download PDF (642 KB)

12/22/2017 - 12:30 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (159 KB)

11/19/2017 - 8:49 pm

DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients

Download PDF (1 MB)

10/20/2017 - 8:55 pm

DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut- Allergic Patients Four to 11 Years of Age

Download PDF (1 MB)

10/12/2017 - 8:48 pm

DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut

Download PDF (1,018 KB)

10/03/2017 - 5:58 pm | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (159 KB)

09/05/2017 - 7:42 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (158 KB)

09/01/2017 - 7:43 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (709 KB)

08/29/2017 - 7:44 pm | Clinical

DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut

Download PDF (323 KB)

08/02/2017 - 7:57 pm | Clinical

DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age

Download PDF (1,023 KB)

07/28/2017 - 7:58 pm | Finance

DBV Technologies Reports First Half 2017 Financial Results

Download PDF (1,015 KB)

07/07/2017 - 8:00 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (57 KB)

07/05/2017 - 8:01 pm | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with Natixis

Download PDF (111 KB)

06/17/2017 - 8:32 pm | Science

DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress

Download PDF (1 MB)

06/15/2017 - 8:34 pm | General Assembly

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

Download PDF (926 KB)

06/12/2017 - 5:07 pm

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

Download PDF (926 KB)

06/01/2017 - 8:38 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (925 KB)

05/12/2017 - 5:29 pm | Corporate | Finance

Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting

Download PDF (158 KB)

05/08/2017 - 9:27 pm | Science

DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn’s Disease at Digestive Disease Week 2017

Download PDF (1,020 KB)

05/02/2017 - 5:32 pm | Conferences | Finance

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (928 KB)

04/28/2017 - 9:29 pm | Finance

DBV Technologies Reports March 31, 2017 Cash Position

Download PDF (927 KB)

04/05/2017 - 9:31 pm | Conferences

DBV Technologies to Attend the 10th Kempen Life Sciences Conference

Download PDF (643 KB)

04/05/2017 - 9:31 pm | Conferences

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (159 KB)

03/30/2017 - 9:32 pm | Clinical | Corporate

DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination

Download PDF (355 KB)

03/22/2017 - 11:30 pm | Corporate | Finance

DBV Technologies Announces Filing of its 2016 “Document de Référence” and Annual Report on Form 20-F

Download PDF (1,008 KB)

03/15/2017 - 7:30 am | Finance

DBV Technologies Reports Full Year 2016 Financial Results

Download PDF (194 KB)

03/10/2017 - 7:30 am | Clinical | Product Candidates

DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children

Download PDF (1 MB)

03/07/2017 - 2:47 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (158 KB)

03/05/2017 - 9:45 pm | Clinical | Conferences

Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children

Download PDF (1 MB)

03/01/2017 - 7:30 am | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (927 KB)

02/20/2017 - 7:30 am | Finance

DBV Technologies Reports December 31, 2016 Cash Position

Download PDF (927 KB)

02/10/2017 - 10:41 pm | Conferences | Corporate | Science

DBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT®

Download PDF (1 MB)

02/05/2017 - 11:34 am | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (155 KB)

02/03/2017 - 7:30 am | Clinical | Product Candidates

DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis

Download PDF (1,020 KB)

01/26/2017 - 7:30 am | Conferences

DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare Conference

Download PDF (927 KB)

01/09/2017 - 7:30 am | Corporate | Finance

DBV Technologies Announces Financial Calendar 2017

Download PDF (121 KB)

01/04/2017 - 5:38 pm | Finance

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

Download PDF (940 KB)

01/04/2017 - 5:10 pm | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (155 KB)

12/07/2016 - 10:57 am | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (155 KB)

11/17/2016 - 7:30 am | Clinical | Product Candidates

DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis

Download PDF (347 KB)

11/16/2016 - 10:57 am | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (155 KB)

11/12/2016 - 1:30 am | Science

DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting

Download PDF (1 MB)

11/10/2016 - 3:00 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (931 KB)

11/08/2016 - 3:01 pm | Clinical | Product Candidates

DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients

Download PDF (150 KB)

11/03/2016 - 3:03 pm | Finance

DBV Technologies Reports September 30, 2016 Cash Position

Download PDF (928 KB)

10/26/2016 - 3:04 pm | Clinical | Product Candidates

DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology

Download PDF (1 MB)

10/24/2016 - 3:05 pm | Clinical | Product Candidates

Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut

Download PDF (1 MB)

10/17/2016 - 3:06 pm | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

Download PDF (155 KB)

09/21/2016 - 3:07 pm | Product Candidates

DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein Allergy

Download PDF (1 MB)

09/06/2016 - 3:08 pm | Clinical | Partnership

DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination

Download PDF (362 KB)

09/01/2016 - 3:09 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (941 KB)

08/01/2016 - 3:10 pm | Clinical

DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy

Download PDF (1 MB)

07/28/2016 - 7:30 am | Finance

DBV Technologies Reports Interim Financial Results for the First Half of 2016

Download PDF (205 KB)

07/11/2016 - 3:12 pm | Finance

Half year update on the DBV Technologies liquidity agreement

Download PDF (923 KB)

07/05/2016 - 3:13 pm | Corporate

DBV Technologies Proudly Welcomes Dr. Lucia Septién as Chief Medical Officer

Download PDF (1,023 KB)

06/27/2016 - 3:14 pm | Clinical

DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children

Download PDF (1,022 KB)

06/21/2016 - 8:31 pm | General Assembly

DBV Announced Results of its 2016 Annual Meeting of Shareholders

Download PDF (927 KB)

06/21/2016 - 3:15 pm | General Assembly

DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys Ferrere

Download PDF (1 MB)

06/16/2016 - 3:17 pm | Conferences

DBV Technologies to Present at the JMP Securities Life Sciences Conference

Download PDF (640 KB)

06/15/2016 - 3:17 pm | Product Candidates | Science

Late-Breaking Presentation at EAACI Highlights Viaskin® Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression

Download PDF (1,023 KB)

06/13/2016 - 3:18 pm | Science

DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT® Provides Sustained Protection Against Anaphylaxis

Download PDF (1 MB)

06/07/2016 - 3:19 pm | Corporate

DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board

Download PDF (1,023 KB)

06/01/2016 - 3:20 pm | Conferences | Science

DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies

Download PDF (2 MB)

05/31/2016 - 3:21 pm | Partnership

DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy

Download PDF (1 MB)

05/30/2016 - 8:30 pm | General Assembly

Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly

Download PDF (943 KB)

05/20/2016 - 3:23 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (941 KB)

04/29/2016 - 3:24 pm | Finance

DBV Technologies Reports March 31, 2016 Cash Position

Download PDF (930 KB)

04/28/2016 - 3:25 pm | Corporate

DBV Technologies Announces Filing of 2015 “Document de Référence” and 2015 Annual Report on Form 20-F

Download PDF (1,010 KB)

04/27/2016 - 3:26 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (941 KB)

04/11/2016 - 3:27 pm | Science

DBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous Immunotherapy

Download PDF (1 MB)

04/07/2016 - 3:28 pm | Finance

DBV Technologies Reports Full Year 2015 Financial Results

Download PDF (1 MB)

03/06/2016 - 3:29 pm | Product Candidates

Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance

Download PDF (2 MB)

03/04/2016 - 3:30 pm | Product Candidates

DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin® Peanut Safety and Efficacy

Download PDF (1 MB)

03/01/2016 - 3:31 pm | Conferences

DBV Technologies to Attend Upcoming Investor Conferences and Events

Download PDF (937 KB)

02/25/2016 - 3:32 pm | Product Candidates

DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin® Peanut

Download PDF (1 MB)

02/15/2016 - 3:33 pm | Finance

DBV Technologies Reports December 31, 2015, Cash Position

Download PDF (925 KB)

02/10/2016 - 3:34 pm | Conferences | Finance

DBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting

Download PDF (1 MB)

02/08/2016 - 3:35 pm | Conferences

DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

Download PDF (642 KB)

01/26/2016 - 3:36 pm | Corporate

DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America

Download PDF (1,013 KB)

01/08/2016 - 3:38 pm | Finance

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

Download PDF (647 KB)

01/08/2016 - 3:37 pm | Finance

DBV Technologies Announces 2016 Financial Calendar

Download PDF (939 KB)

01/07/2016 - 3:39 pm | Finance

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

Download PDF (647 KB)

12/10/2015 - 6:29 pm | Science

First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn’s & Colitis Foundation of America’s 2015 Advances in IBD Conference (AIBD)

Download PDF (1 MB)

12/07/2015 - 7:00 pm | Clinical | Product Candidates

DBV Technologies Announces Initiation of Phase III Study of Viaskin® Peanut for the Treatment of Peanut Allergic Children

Download PDF (1 MB)

11/18/2015 - 7:01 pm | Clinical | Science

DBV Technologies to Present Preclinical Data on its Viaskin® Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting

Download PDF (1 MB)

11/12/2015 - 7:02 pm | Clinical

DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis

Download PDF (560 KB)

11/03/2015 - 7:04 pm | Corporate | Finance

DBV Technologies Reports Interim Financial Results for the third quarter of 2015

Download PDF (515 KB)

10/22/2015 - 7:05 pm | Corporate

DBV Technologies Announces the Appointment of Michael J. Goller to its Board of Directors

Download PDF (1 MB)

10/14/2015 - 7:07 pm | Clinical | Product Candidates

DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk

Download PDF (511 KB)

10/05/2015 - 7:08 pm | Clinical | Product Candidates

Follow-Up Study of Viaskin® Peanut Shows Significant Increase in Peanut Consumption and Treatment Benefit in Peanut Allergic Children

Download PDF (821 KB)

09/11/2015 - 7:09 pm | Corporate | Finance

DBV Technologies To Enter SBF 120 Index

Download PDF (367 KB)

09/08/2015 - 7:10 pm | Conferences

DBV Technologies Invited to Present at the Royal Society of Medicine 11th Medical Innovations Summit

Download PDF (356 KB)

09/03/2015 - 7:11 pm | Conferences | Corporate

DBV Technologies to Attend Upcoming Investor Conferences and Events

Download PDF (509 KB)

08/31/2015 - 7:12 pm | General Assembly

DBV Technologies’ Extraordinary General Assembly on September 21, 2015

Download PDF (942 KB)

08/26/2015 - 10:17 pm | Conferences | Finance

DBV Technologies to Attend the Goldman Sachs European Biotech Symposium

Download PDF (69 KB)

07/28/2015 - 10:18 pm | Corporate | Finance

DBV Technologies Reports Financial Results   for the First Six Months of 2014  

Download PDF (187 KB)

07/27/2015 - 7:13 pm | Corporate | Finance

DBV Technologies Reports Interim Financial Results for the First Half of 2015

Download PDF (659 KB)

07/20/2015 - 7:14 pm | Finance

DBV Technologies Announces Closing of $281.5 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Download PDF (499 KB)

07/17/2015 - 10:19 pm | Clinical | Product Candidates

DBV Technologies Completes last “food challenge” visit of last PeanutAllergic patient in VIPES Phase IIb Clinical Study

Download PDF (116 KB)

07/15/2015 - 7:15 pm | Corporate | Finance

DBV Technologies Announces Pricing of Underwritten Public Offering of Ordinary Shares

Download PDF (501 KB)

07/14/2015 - 7:16 pm | Corporate | Finance

DBV Technologies Announces Launch of Proposed Underwritten Public Offering of Ordinary Shares

Download PDF (501 KB)

07/08/2015 - 7:17 pm | Science

IND Acceptance from FDA for a proof-ofconcept trial using Viaskin® Milk in MilkInduced Eosinophilic Esophagitis in Children

Download PDF (638 KB)

07/02/2015 - 11:30 pm | Corporate | Finance

DBV Technologies announces the filing of a registration statement on Form F-1 in view of an offering of new shares in the form of American Depositary Shares, as well as the filing of its Reference Document

Download PDF (649 KB)

07/02/2015 - 6:30 pm | Corporate | Finance

Half year update on the DBV Technologies liquidity agreement

Download PDF (199 KB)

06/30/2015 - 7:20 pm | Corporate

DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin® Milk in Pediatric Cow’s Milk Allergy

Download PDF (641 KB)

06/26/2015 - 7:21 pm | Corporate

DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer

Download PDF (516 KB)

06/23/2015 - 11:00 am | Corporate

DBV Technologies’ June 23, 2015 Combined Shareholders’ Meeting

Download PDF (504 KB)

06/23/2015 - 12:00 am | Corporate

DBV Technologies Confirms Planned Initiation of Viaskin® Peanut Global Phase III Clinical Trial in Children Following Endof-Phase II Meeting with FDA and PIP approval by EMA

Download PDF (799 KB)

06/10/2015 - 7:24 pm | Science

Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine

Download PDF (158 KB)

06/08/2015 - 7:25 pm | Conferences | Science

DBV Technologies Presents Clinical and Scientific Data at the EAACI Congress

Download PDF (158 KB)

06/04/2015 - 7:27 pm | Corporate | Science

DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin® Peanut for the Treatment of Peanut Allergic Children

Download PDF (665 KB)

06/02/2015 - 7:28 pm | Conferences | Finance

DBV Technologies to Attend Upcoming Investor Conferences

Download PDF (651 KB)

05/20/2015 - 11:30 am | Corporate

Publication of the Resolutions Proposed to the Mixed General Assembly of DBV

Download PDF (1,008 KB)

05/05/2015 - 7:31 pm | Conferences | Corporate | Finance

DBV Technologies to Present at Upcoming Investor Conferences

Download PDF (368 KB)

04/30/2015 - 7:32 pm | Corporate | Finance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Download PDF (2 MB)

04/29/2015 - 7:34 pm | Corporate | Finance

Topline Financial Results for First Three Months of 2015

Download PDF (228 KB)

04/28/2015 - 7:47 pm | Corporate | Finance

DBV Technologies Selected to Enter Euronext’s Tech 40 Label

Download PDF (354 KB)

04/15/2015 - 7:49 pm | Conferences | Corporate | Science

DBV Technologies to Present Viaskin® Data at the 2015 EAACI Congress

Download PDF (800 KB)

04/09/2015 - 7:50 pm | Corporate | Product Candidates

DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children

Download PDF (668 KB)

03/25/2015 - 7:51 pm | Corporate | Finance

DBV Technologies Reports Full Year 2014 Financial Results

Download PDF (263 KB)

03/10/2015 - 7:52 pm | Corporate

DBV Technologies Appoints Daniel Soland to Board of Directors

Download PDF (514 KB)

03/06/2015 - 7:53 pm | Conferences | Finance

DBV Technologies to Present at Upcoming Investor Conferences

Download PDF (637 KB)

02/24/2015 - 7:54 pm | Conferences | Science

Viaskin® Data Presented at AAAAI Meeting Show Safety and Efficacy in the Treatment of Food Allergies

Download PDF (820 KB)

02/13/2015 - 7:56 pm | Corporate | Science

DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board

Download PDF (92 KB)

02/03/2015 - 7:57 pm | Conferences | Finance

DBV Technologies to Present at the 2015 Leerink Partners Global Healthcare Conference in New-York (USA)

Download PDF (75 KB)

02/03/2015 - 6:30 pm | Conferences | Science

Largest Presence Ever of DBV Technologies at 2015 Allergy Meeting

Download PDF (103 KB)

01/29/2015 - 7:30 am | Corporate | Finance

DBV Technologies Announces Topline Financial Results   for Full Year 2014  

Download PDF (170 KB)

01/14/2015 - 6:00 pm | Corporate | Finance

Half year update on the DBV Technologies liquidity agreement

Download PDF (128 KB)

01/12/2015 - 7:30 am | Science

DBV Technologies Announces Publication in the Journal of Allergy and Clinical Immunology of Data Demonstrating that Epicutaneous Immunotherapy may Influence the Natural History of Allergy

Download PDF (120 KB)

01/08/2015 - 7:30 am | Corporate

DBV Technologies Provides Organizational Update

Download PDF (111 KB)

11/20/2014 - 10:09 pm | Clinical | Product Candidates

DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow’s Milk Allergy

Download PDF (105 KB)

10/23/2014 - 10:10 pm | Corporate | Finance

Global offering of DBV Technologies ordinary shares

Over-allotment option exercised in full
Download PDF (110 KB)

10/22/2014 - 10:11 pm | Corporate | Finance

DBV Technologies S.A. Announces Pricing of Global Offering

Download PDF (111 KB)

10/20/2014 - 10:13 pm | Corporate | Finance

DBV Technologies S.A. Announces Proposed Global Offering

Download PDF (145 KB)

10/14/2014 - 10:14 pm | Conferences | Finance

DBV Technologies Announces Topline Financial Results for First Nine Months 2014

Download PDF (83 KB)

09/22/2014 - 10:15 pm | Clinical | Science

DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut’s Phase IIb Clinical Trial in Peanut Allergy

Download PDF (149 KB)

07/17/2014 - 10:20 pm | Clinical | Partnership | Product Candidates

Consortium of Food Allergy Research Completes Recruitment of NIH-sponsored CoFar6 Phase II Trial with DBV’s Viaskin® Peanut in Treatment of Peanut Allergy

Download PDF (108 KB)

06/16/2014 - 10:21 pm | Corporate | Finance

DBV Technologies to Present at Upcoming US Investors Conferences

Download PDF (86 KB)

06/10/2014 - 11:35 pm | Conferences | Science

Five Scientific Communications at the European Academy of Allergy and Clinical Immunology Congress Further Support DBV’s EPITTM Disease Modifying Effect

Download PDF (116 KB)

05/13/2014 - 11:40 pm | Clinical | Partnership | Product Candidates

DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children

Download PDF (112 KB)

05/12/2014 - 11:43 pm | Corporate | Finance

DBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014

Download PDF (107 KB)

04/17/2014 - 11:44 pm | Corporate | Finance

DBV Technologies publishes its 2013 Registration Document and its 2013 Annual Financial Report

Download PDF (137 KB)

04/16/2014 - 11:45 pm | Clinical | Conferences | Product Candidates

DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPITTM) with Viaskin® at the French Congress of Allergy

CFA 2014 - Clinical Abstract
Download PDF (142 KB)

04/16/2014 - 6:10 am | Clinical | Conferences | Product Candidates

CFA 2014 – Clinical Abstract

DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin® at the French Congress of Allergy
Download PDF (142 KB)

04/15/2014 - 11:46 pm | Corporate | Finance

DBV Technologies Announces Topline Financial Results   for First Three Months 2014  

Download PDF (182 KB)

04/09/2014 - 11:48 pm | Corporate | Partnership | Science

DBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapy

Download PDF (129 KB)

04/07/2014 - 11:49 pm | Corporate

DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy

Download PDF (108 KB)

03/25/2014 - 11:49 pm | Conferences | Science

DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014

Download PDF (129 KB)

03/17/2014 - 11:51 pm | Clinical | Corporate | Finance

DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update

Download PDF (119 KB)

03/04/2014 - 11:52 pm | Conferences | Science

Presentation and Publication of Research at AAAAI Demonstrates EPITTM’s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect

Download PDF (113 KB)

02/18/2014 - 11:53 pm | Corporate | Partnership | Science

DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease

Download PDF (134 KB)

01/30/2014 - 11:54 pm | Corporate | Finance

DBV Technologies Reports Full Year 2013 Topline Financial Results

Download PDF (114 KB)

12/17/2013 - 3:25 pm | Clinical | Corporate | Product Candidates | Science

DBV provides 2013 year-end summary and news flow guidance for 2014

Download PDF (141 KB)

12/13/2013 - 3:26 pm | Clinical | Conferences | Product Candidates | Science

Dr. Hugh Sampson presents Epicutaneous Immunotherapy for Food Allergy at the World Allergy Organization Conference

Download PDF (105 KB)

11/26/2013 - 3:28 pm | Corporate | Partnership | Science

DBV Technologies Enters into Collaboration Agreement with BioNetAsia and University of Geneva on Whooping Cough Booster Vaccine

Download PDF (156 KB)

11/14/2013 - 3:29 pm | Corporate | Finance

DBV Technologies announces the completion of a €29.9m private placement with a majority placed with US investors

Download PDF (206 KB)

10/24/2013 - 3:30 pm | Clinical | Partnership | Product Candidates

NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies’ Viaskin® Peanut in the treatment of peanut allergy

Download PDF (117 KB)

10/22/2013 - 3:31 pm | Corporate | Partnership | Science

DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin® for Refractory Hemophilia A Disease

Download PDF (119 KB)

10/18/2013 - 3:34 pm | Clinical | Corporate | Partnership | Product Candidates | Science

Stallergenes and DBV Technologies Announce Respiratory Allergy Research and Development Collaboration for Birch Pollen

Download PDF (154 KB)

10/15/2013 - 3:35 pm | Clinical | Corporate | Finance

DBV Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin® Peanut

Download PDF (116 KB)

09/04/2013 - 3:36 pm | Clinical | Product Candidates

DBV Technologies initiates a long-term follow-up study of Viaskin Peanut

Download PDF (94 KB)

07/08/2013 - 3:37 pm | Clinical | Product Candidates

DBV Technologies completes enrollment of Phase IIb VIPES study, the first-ever global trial in desensitization to peanut allergy

Download PDF (141 KB)

06/28/2013 - 3:38 pm | Conferences | Science

DBV Technologies announces breakthrough Data Presentations at EAACI-WAO Congress

Download PDF (84 KB)

06/20/2013 - 3:39 pm | Clinical | Partnership | Product Candidates

Viaskin Peanut demonstrates strong efficacy trend in severely peanut-allergic children in 18-month results of ARACHILD pilot study

Download PDF (126 KB)

05/16/2013 - 3:40 pm | Clinical | Partnership | Product Candidates | Science

Stallergenes and DBV Technologies enter into partnership for the development of innovative treatment of respiratory allergies

Download PDF (142 KB)

05/07/2013 - 3:41 pm | Corporate | Partnership | Science

DBV Technologies and Mount Sinai Hospital enter into a Research Collaboration Agreement

Download PDF (93 KB)

04/25/2013 - 3:42 pm | Corporate | Finance

DBV Technologies publishes its 2012 Registration Document and its 2012 Annual Financial Report

Download PDF (149 KB)

03/05/2013 - 3:43 pm | Corporate | Finance | Partnership

DBV Technologies enters into a strategic manufacturing agreement with Sanofi

Download PDF (95 KB)

03/04/2013 - 3:44 pm | Corporate | Finance | Science

DBV Technologies reports Full Year 2012 financial results and provides R&D update

Download PDF (213 KB)

01/31/2013 - 3:45 pm | Clinical | Corporate | Finance | Science

DBV Technologies Reports Full Year 2012 Topline and Provides an Update on R&D Activities

Download PDF (102 KB)

01/15/2013 - 3:46 pm | Corporate | Partnership | Science

DBV Technologies and INRA receive funding to develop pediatric bronchiolitis (‘RSV’) vaccine: RSV-NanoViaSkin

Download PDF (172 KB)

12/18/2012 - 7:00 am

DBV Technologies’ 2013 Financial calendar

Download PDF (85 KB)

11/14/2012 - 5:20 pm | Clinical | Corporate | Product Candidates | Science

DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children

Download PDF (139 KB)

10/16/2012 - 9:46 am | Corporate | Science

DBV Technologies and Centre d’Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement

Download PDF (284 KB)

10/15/2012 - 4:00 pm | Corporate | Finance

First nine months topline and clinical and business highlights

Download PDF (131 KB)

08/02/2012 - 5:42 pm | Clinical | Corporate | Product Candidates

DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults

Download PDF (138 KB)

07/26/2012 - 9:19 am | Clinical | Corporate | Science

Half Year 2012 results and R&D highlights: DBV Technologies on track

Download PDF (140 KB)

07/19/2012 - 5:30 pm | Corporate | Science

DBV Technologies welcomes Mr. Stef Koppelman as its new General Scientific Advisor

Download PDF (120 KB)

06/18/2012 - 11:15 am | Clinical | Conferences | Product Candidates

DBV Technologies presents detailed results of a clinical study showing that VIASKIN® is safe and well-tolerated by peanut-allergic patients at the EAACI congress

Download PDF (129 KB)

06/18/2012 - 11:07 am | Clinical | Product Candidates

Positive interim clinical data in peanut allergic children treated with VIASKIN PEANUT

Download PDF (333 KB)

05/31/2012 - 11:20 am | Corporate | Science

Professor Hugh Sampson joins Scientific Advisory Board of DBV Technologies

Download PDF (124 KB)

05/15/2012 - 10:53 am | Clinical | Finance | Science

First quarter 2012 topline, scientific activity and upcoming clinical data

Download PDF (134 KB)

05/10/2012 - 11:01 am | Corporate

DBV Technologies welcomes Charles Ruban as Chief Development Officer

Download PDF (114 KB)

03/28/2012 - 10:28 am | Corporate | Finance

Successful Initial Public Offering (IPO) for DBV Technologies

Download PDF (401 KB)

02/28/2012 - 9:32 am | Clinical | Product Candidates | Science

Viaskin Peanut receives FDA “Fast Track Designation”

Download PDF (18 KB)

01/31/2012 - 10:05 am | Corporate | Finance

DBV Technologies announces the filing of its “Document de Base” with the French Autorité des marchés financiers

Download PDF (501 KB)

12/06/2011 - 10:26 am | Corporate | Finance

DBV Technologies introduces its new Chief Financial Officer

Download PDF (109 KB)

09/21/2011 - 10:32 am | Corporate

DBV Technologies moves to Bagneux

Download PDF (201 KB)

06/08/2011 - 9:09 am | Clinical | Science

DBV Technologies VIASKIN® technology has been chosen to feature on the cover of the European Journal of Allergy and Clinical Immunology June 2011 issue in its timeline “100 years allergen specific immunotherapy.”

Download PDF (2 MB)

01/18/2011 - 10:47 am | Corporate | Science

DBV Technologies elects George Horner as non­ executive Chairman

Download PDF (181 KB)

01/08/2011 - 9:58 am | Corporate | Science

DBV Technologies is very proud to have been chosen to feature on the cover of the Journal of Allergy and Clinical Immunology January 2011 issue

Download PDF (692 KB)

01/05/2011 - 10:57 am | Corporate | Finance

DBV Technologies closes $25.5 (€19,4) million Series ‘C’ financing round

Download PDF (107 KB)

09/23/2010 - 9:52 am | Corporate | Finance | Product Candidates

DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN®

Download PDF (214 KB)

09/01/2010 - 10:00 am | Clinical | Product Candidates

VIASKIN® PEANUT Selected for U.S. Consortium of Food Allergy Research’s Peanut Allergy Desensitization Trial

Download PDF (211 KB)

07/06/2010 - 10:02 am | Clinical | Product Candidates

DBV Technologies Receives IND Clearance From FDA to Begin Clinical Trial in Peanut Allergy

Download PDF (207 KB)

06/14/2010 - 10:05 am | Corporate | Science

DBV Technologies expands Scientific Advisory Board with appointment of leading US allergy specialists

Download PDF (205 KB)

12/18/2009 - 12:50 am | Corporate

DBV Technologies appoints Professor Robert Zeiger to its Scientific Advisory Board

Download PDF (208 KB)

10/19/2009 - 12:47 am | Corporate

DBV Technologies appoints Professors Gideon Lack and Philippe Eigenmann to its Scientific Advisory Board

Download PDF (208 KB)

04/15/2009 - 12:45 am | Corporate | Partnership

DBV Technologies signs strategic agreement with Assistance Publique-Hôpitaux de Paris (AP-HP) office of technology transfer and industrial partnerships

Download PDF (206 KB)

02/19/2009 - 12:40 am | Corporate

DBV Technologies expands its Board of Directors

Download PDF (202 KB)

01/22/2009 - 11:20 am | Corporate | Finance

DBV Technologies raises €6 million in Series B investment and secures new corporate investor

Download PDF (197 KB)

11/13/2007 - 11:23 am | Corporate | Science

DBV Technologies Strengthens Board of Directors and Scientific Advisory Board

Download PDF (211 KB)

01/23/2006 - 11:25 am | Corporate | Finance

Sofinnova and Apax Partners invest €12 million in DBV Technologies

Download PDF (218 KB)